Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Revised Accutane Label Describes Lack Of PK Effect On Ortho-Novum

Executive Summary

Roche has revised Accutane labeling to contain drug interaction information showing a lack of pharmacokinetic effect on Ortho-McNeil's oral contraceptive Ortho-Novum

You may also be interested in...

Celgene risk management plan patents

Celgene is in discussions with companies interested in licensing its patents covering the STEPS risk management program for Thalomid, President Sol Barer says July 22. Celgene holds five patents covering risk management programs that link patients, pharmacists and physicians through computerized databases. The patents are holding up implementation of revised risk management plans for isotretinoin (Roche's Accutane and generics) and could pose an obstacle to creation of a risk management program for Allergan's Tazoral (1"The Pink Sheet" July 19, 2004, p. 3)...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts